Clinical Charts
Emetogenic potential (high, moderate, low, or minimal risk) of oral and injectable antineoplastic agents.
Drugs in the Pipeline
Mirvetuximab soravtansine is an antibody-drug conjugate comprised of a FRα-binding antibody, a cleavable linker, and a potent tubulin-targeting agent.
News
The approval was based on data demonstrating that the biosimilar product and the reference product were highly similar, and that there were no clinically meaningful differences between the agents.
Clinical Charts
A comparative list of biosimilars approved by the FDA including their reference products, dosage forms and indications.
Clinical Charts
FDA-Approved treatment options for individuals with ovarian cancer including dosing.
Clinical Charts
Chemotherapeutic and biologic agents for the treatment of non-small cell lung cancer (NSCLC).
Clinical Charts
Colorectal cancer treatment regimen chart.
Drug Monograph Updates
The summary below gives an overview of important additions and changes MPR has made to its drug database through the end of December. The chart below provides highlights of key monograph updates made this month (not an inclusive list). Click on the name of the drugs to view the full monographs on eMPR.com. Key: D=Dosing,…
Drug Monograph
Bevacizumab-awwb 100mg, 400mg; per vial; soln for IV infusion after dilution; preservative-free.
Select the therapeutic use below to view the corresponding drug monograph
Visit the related Resource Center for drug monographs, news, CME and other clinical tools for this drugs’ particular therapeutic area.